Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAB2 | O43741 | 1/20 | 0.48 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.48 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.48 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.48 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.48 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.48 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.47 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.44 |
| ▸ | LTA4H | P09960 | 3/20 | 0.44 |
| ▸ | HRH2 | P25021 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | ATP4A | P20648 | 3/20 | 0.41 |
| ▸ | ATP4B | P51164 | 3/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5786655 | 0.87 | TGFBR1 (0.57) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL5788739 | 0.85 | IGF1R (0.51) | TGFBR1ACHEKDM4E | |
| SCHEMBL5789751 | 0.80 | MAPK13 (0.46) | — | |
| SCHEMBL5789564 | 0.77 | IGF1R (0.48) | TGFBR1KDM4E | |
| SCHEMBL5788026 | 0.76 | HRH3 (0.49) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL5790097 | 0.74 | CDK2 (0.43) | KDM4E | |
| SCHEMBL5786911 | 0.74 | TGFBR1 (0.39) | TGFBR1HRH3KDM4E | |
| SCHEMBL5789344 | 0.73 | TGFBR1 (0.43) | TGFBR1HRH3KDM4E | |
| SCHEMBL5790032 | 0.73 | GAA (0.46) | KDM4E | |
| SCHEMBL5791222 | 0.71 | TGFBR1 (0.40) | TGFBR1HRH3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1543003-B1 | IMIDAZO¬1,2-A|PYRIDINES | SMITHKLINE BEECHAM CORP (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20050234029-A1 | Compounds | DODIC NERINA | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234029-A1 | Compounds | SMAD3, SMAD2, ACVR1 | PRKAB2 474/4885PRKAG1 527/4885PRKAA2 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.